- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02843321
Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination (CYNTAX)
November 21, 2016 updated by: David Gottlieb, University of Sydney
Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination to Enhance Infection-Specific Immune Reconstitution Post-Allogeneic Stem Cell Transplantation
To assess the safety and biological efficacy of prophylactically administered donor-derived multi-infection specific cytotoxic T lymphocytes (CTLs) (targeting cytomegalovirus (CMV), Adenovirus (Adv), Epstein Barr virus (EBV), Varicella-Zoster virus (VZV), Influenza (Flu), BK virus (BKV), and Aspergillus (Asp)) combined with early immunisation with Influenza and VZV vaccines for the prevention of viral and fungal infection following allogeneic blood or marrow stem cell transplantation.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study will analyse the safety and biological efficacy of administering the investigational products (donor-derived T cells stimulated with viral and fungal antigen expressing DC combined with Flu and VZV immunisation), for the prophylaxis of viral and fungal reactivation and/or infection following allogeneic blood or marrow transplantation.
The cells will be given prophylactically a minimum of 28 days after transplantation followed by administration of the Flu and VZV vaccines 24 to 72 hours later.
The AIMS are to study the safety of combining CTL infusions and vaccination as well as their effect on reconstitution of infection-specific immunity, viral and Aspergillus reactivation and infection rates after transplantation, viral load, and use of antiviral and antifungal pharmacotherapy for specific infections.
The investigators will also evaluate the safety of infusions and vaccinations with respect to the development adverse events within the first 12 months post transplant.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Westmead, Sydney, New South Wales, Australia, 2145
- Westmead Hospital Department of Haematology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients undergoing myeloablative or non-myeloablative allogeneic transplantation from an HLA (A, B and DR) identical or 1-3 antigen mismatched family or unrelated donor.
- Transplant performed for any type of non-malignant condition or haematological malignancy including but not limited to acute and chronic leukaemia, myelodysplasia, non Hodkgins and Hodgkin lymphoma or myeloma.
- Recipients of peripheral blood or bone marrow stem cells.
- Adequate hepatic and renal function (< 3 x upper limit of normal for AST (SGOT), ALT (SGPT), < 2 x upper limit of normal for total bilirubin, serum creatinine).
- Estimated life expectancy of at least 6 months.
- Patient (or legal representative) has given informed consent
Exclusion Criteria:
- Use of anti-lymphocyte globulin (ALG, ATG, Campath or other broad spectrum lymphocyte antibody) given in the 4 weeks immediately prior to infusion or planned within 4 weeks after infusion.
- Grade II or greater graft versus host disease within 1 week prior to infusion.
- Prednisone or methylprednisone at a dose of > 1 mg/kg (or equivalent in other steroid preparations) administered within 72 hours prior to cell infusion.
- Allergies to eggs or components of the Fluvax or Varivax vaccines.
- Privately insured in or outpatients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T-cell infusion
Infusion of donor-derived T cells.
Non randomised, prevention study arm
|
Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of infection-specific T-cell infusion and vaccination
Time Frame: 1 week
|
Presence of acute infusion related toxicities
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in infection specific immune reconstitution
Time Frame: 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, 6 months, 9 months, 12 months (post T-cell infusion)
|
1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, 6 months, 9 months, 12 months (post T-cell infusion)
|
Change in CMV, EBV and BKV load based on quantitive PCR
Time Frame: 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, 6 months, 9 months, 12 months (post T-cell infusion)
|
1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, 6 months, 9 months, 12 months (post T-cell infusion)
|
Use of specific anti-viral pharmacotherapy
Time Frame: 12 months (post T-cell infusion)
|
12 months (post T-cell infusion)
|
Use of systemic anti-fungal drugs including amphotericin and azoles
Time Frame: 12 months (post T-cell infusion)
|
12 months (post T-cell infusion)
|
Incidences of GVHD
Time Frame: 12 months (post T-cell infusion)
|
12 months (post T-cell infusion)
|
Number of in-hospital days following first discharge post transplant
Time Frame: 12 months (post T-cell infusion)
|
12 months (post T-cell infusion)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Gottlieb, Professor, Westmead Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Anticipated)
December 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
May 18, 2016
First Submitted That Met QC Criteria
July 22, 2016
First Posted (Estimate)
July 25, 2016
Study Record Updates
Last Update Posted (Estimate)
November 22, 2016
Last Update Submitted That Met QC Criteria
November 21, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Cyntax
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Complication of Transplant
-
Northwestern UniversityTerminatedComplication of TransplantUnited States
-
University of CincinnatiUniversity of Colorado, Denver; Children's Hospital Medical Center, CincinnatiCompletedComplication of TransplantUnited States
-
Massachusetts General HospitalCompletedComplication of TransplantUnited States
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain
-
Instituto de Investigacion Sanitaria La FeCompletedUnspecified Complication of Liver TransplantSpain
-
The University of Texas Medical Branch, GalvestonCompletedUnspecified Complication of Lung TransplantUnited States
-
Duke UniversityWithdrawnUnspecified Complication of Bone Marrow TransplantUnited States
-
Assiut UniversityNot yet recruitingLiver Transplant; Complications | Renal Complication of Procedure
-
Erasmus Medical CenterUniversity Medical Center Groningen; Leiden University Medical CenterRecruitingComplication of Surgical Procedure | Liver Transplant | Organ PerfusionNetherlands
-
Western Sydney Local Health DistrictNot yet recruitingKidney Transplant Rejection | Transplant Complication
Clinical Trials on T-cell infusion, influenza vaccination
-
Sheba Medical CenterUnknown
-
Sheba Medical CenterUnknownMultiple SclerosisIsrael
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruitingAcute T-lymphoblastic Leukemia | Acute T-lymphoblastic LymphomaChina
-
Massachusetts General HospitalDana-Farber Cancer Institute; University of RegensburgCompletedKidney Failure, Kidney TransplantUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnLymphoma | Lymphoma, B-Cell | LeukemiaUnited States
-
Mario ArpinatiEuropean CommissionRecruitingChronic Graft Versus Host DiseaseItaly
-
Wuhan Union Hospital, ChinaGuangzhou Bio-gene Technology Co., LtdNot yet recruitingSystemic Lupus Erythematosus
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting